U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07530575) titled 'Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCO' on Aug. 28, 2025.
Brief Summary: This research study aims to determine if a probiotic called Limosilactobacillus fermentum CRL 1446 can improve the health of people at risk for cardiovascular disease.
The study will be conducted with volunteers who will randomly consume either the probiotic or a placebo (a capsule without the probiotic), without knowing which one they are taking. The researchers will analyze how the probiotic affects blood sugar control, body composition, inflammation, and oxidative stress. The goal is to determine if this beneficial bacterium, by influenci...